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Buruli ulcer, the third most common mycobacterial dis-
ease worldwide, rarely affects travelers and is uncommon 
in the United States. We report a travel-associated case 
imported	 from	Australia	 and	 review	 3	 previous	 cases	 di-
agnosed and treated in the United States. The differential 
diagnoses for unusual chronic cutaneous ulcers and those 
nonresponsive to conventional therapy should include My-
cobacterium ulcerans infection.
Buruli ulcer disease, caused by Mycobacterium ulcer-ans, is the third most common mycobacterial disease 
worldwide. Cases are concentrated in sub-Saharan Africa 
but also occur in subtropical and nontropical regions (e.g., 
Australia and Japan) (1). M. ulcerans disease is not endem-
ic to the United States, but rare cases have been reported 
in travelers returning from regions where the organism is 
endemic (2–4). We describe M. ulcerans infection in a man 
who returned to the United States after living abroad and 
review M. ulcerans cases reported in 3 travelers.
The Case
In December 2012, after unsuccessful treatment else-
where, a 63-year-old white man was referred to the Vet-
erans Affairs Medical Center, St. Louis, Missouri, USA, 
for evaluation of skin ulcers. Previous medical history indi-
cated hypertension and hyperlipidemia. The patient sought 
care in April 2012 for a persistent, nonpainful ulcer (1-cm 
diameter) on his right medial calf (Figure). No previous 
episodes or other symptoms of infection were reported. 
The patient had lived abroad for >10 years and had recently 
returned to the United States from Queensland, Australia, 
where he spent his last month hiking in the Daintree Rain-
forest. His health care providers recommended topical an-
timicrobial drugs and wound care, and a punch biopsy was 
obtained but the specimen was not stained or cultured for 
acid-fast bacilli (AFB). Pathologic findings on the biopsy 
specimen were nonspecific (reactive epidermal changes 
and ulceration).
Between April and July 2012, the ulcer increased to 
4 cm despite multiple debridements. In September a pain-
ful, warm, erythematous lesion developed on the patient’s 
left great toe. He consulted physicians in numerous sub-
specialties and underwent 2 more biopsies; specimens were 
not initially stained or cultured for AFB. Pathologic find-
ings from the specimens showed extensive necrosis with-
out granulomas. The ulcers were diagnosed as pyoderma 
gangrenosum with bacterial superinfection, and treatment 
was initiated with oral antimicrobial drugs (amoxicillin/
clavulanate 875/125 mg twice daily) and prednisone (60 
mg/day). Transient improvement occurred, but in late No-
vember, the toe lesion worsened.
When the patient was referred to the Veteran’s Affairs 
Medical Center in December 2012, biopsies were again 
obtained; pathologic evaluation showed extensive necrosis 
(without granulomas) and numerous AFB. Fresh frozen tis-
sue was sent to the Centers for Disease Control and Pre-
vention (CDC; Atlanta, GA, USA) for mycobacterial test-
ing. Empiric treatment with levofloxacin, doxycycline, and 
azithromycin was initiated for nontuberculous mycobacte-
rial infection, and the previously prescribed prednisone was 
rapidly tapered and stopped. At CDC, immunohistochemi-
cal testing of tissue for mycobacteria showed extensive ba-
cilli. DNA extracted from biopsy samples was evaluated by 
PCR targeting 16s rRNA and the IS2402 insertion element 
(5). Sequences of IS2404 amplicons were 100% identical 
with those for Mycobacterium ulcerans. Tissue cultured 
(30°C) at CDC grew AFB after 3 months (toe specimen) 
and 4 months (calf specimen); 16S rRNA gene sequencing 
confirmed a Mycobacterium species, most closely match-
ing M. marinum or M. ulcerans.
Therapy, guided by World Health Organization rec-
ommendations (1), was changed to rifampin (900 mg/day 
or 10 mg/kg bodyweight), clarithromycin (1,000 mg/day), 
and moxifloxacin (400 mg/day). In February 2014, after 
15 months’ of antimicrobial drug treatment, debridement, 
and skin grafting to the left foot, the lesions were com-
pletely healed.
Conclusions
Imported M. ulcerans disease is exceedingly rare, even 
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occur, diagnosis is often delayed. In addition to the case 
reported here, 3 other cases imported to the United States 
have been reported in the literature since 1967 (2–4).
The 4 M. ulcerans cases diagnosed in the United States 
were in men (median age 35 years, range 20–63) (Table). 
Lesions were located on the upper (25%) and lower (75%) 
extremities, similar to cases in Africa, where lesions com-
monly develop on the extremities of adults and on the 
trunk, head, neck, and upper limbs of children (6). Specific 
exposures were not identified in 3 of the US patients; the 
fourth had exposure to fresh water, a known risk factor (6). 
The 2012 imported US case is similar to cases in Australia, 
where patients have a median age of 61 years at diagnosis, 
and most have single lesions (95%) involving lower limbs 
(61%). However, in Australia, the median time from symp-
tom onset to diagnosis is 42 days, consistent with greater 
familiarity with the disease (7).
The 3 persons with the prior cases of imported M. ul-
cerans disease in the United States had traveled to west-
ern Africa; the case-patient described herein had returned 
from Australia. Most M. ulcerans cases in Australia are 
linked to temperate, coastal Victoria and tropical, northern 
Queensland (8). Persons with cases imported to other M. 
ulcerans–nonendemic countries mostly traveled to Africa 
(1 traveled to South America), where the disease is present 
but uncommon (9–12).
In regions where M. ulcerans disease is endemic, it is 
readily recognized on the basis of lesion appearance and 
chronicity. In areas of Australia where Buruli ulcer dis-
ease is nonendemic, diagnosis is delayed (13). A hallmark 
of imported cases is the difficulty in arriving at a diagnosis 
due to nonfamiliarity with the disease. For the 4 imported 
US cases, the median time to empiric antimycobacterial 
therapy was 20 weeks, and the median time to definitive 
diagnosis was 8 months. The differential diagnosis for M. 
ulcerans disease is broad, spanning infectious and non-
infectious etiologies, including filariasis, phycomycosis, 
resolving furuncle, and pyoderma gangrenosum. Samples 
from the case-patients were uniformly AFB smear-posi-
tive, and for 1 case in which the culture failed to grow M. 
ulcerans, diagnosis was made by clinical and epidemio-
logic history and presence of AFB in tissue. Because the 
organism is slow growing, prolonged culture (>3 months) 
at low temperatures is required. A hallmark of M. ul-
cerans histopathology is the absence of granulomas and 
presence of extensive necrosis caused by the organism’s 
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Figure. Progression of lesions caused by Mycobacterium ulcerans	 infection	before,	during,	and	after	 treatment.	A–C)	Left	 foot	before	
treatment.	D)	Left	lower	leg	during	treatment.	E)	Right	calf	before	treatment.	F)	Right	calf	after	treatment.	G,	H)	Left	foot	after	treatment.
secretion of mycolactone toxin, which suppresses the 
host’s immune response (7). The absence of granulomas 
on hematoxylin and eosin staining may result in tissue not 
being stained for AFB unless clinicians have a high in-
dex of suspicion. Furthermore, depending on the bacterial 
load and focal distribution, bacteria may not be detected 
by AFB staining. Molecular analysis of tissue is the most 
sensitive and specific method for rapid and confirmatory 
diagnosis of M. ulcerans and should be pursued when dis-
ease is suspected (14).
Treatment of M. ulcerans disease has changed mark-
edly over the last several decades. Prior to the early 2000s, 
availability of effective drugs was limited, so surgery was 
the primary treatment. However, combination therapy with 
streptomycin, rifampin, and surgery (including skin graft-
ing) has been shown to be effective (1), and some cases can 
be managed with medical therapy alone. Standard antimi-
crobial treatment, according to World Health Organization 
guidelines, consists of administering rifampin (10 mg/kg 
body weight daily by mouth) for 8 weeks and streptomy-
cin (15 mg/kg body weight daily by intramuscular injec-
tion) for 8 weeks (1). Extensive clinical experience has also 
shown a combination of oral antimicrobial drugs (rifampin 
with clarithromycin or moxifloxacin) to be effective against 
Buruli ulcer disease (15). Of the 4 reported US cases, 1 re-
quired surgery alone and 3 required drug treatment and sur-
gery. Response to therapy has been favorable: 2 US cases 
were cured by treatment with oral antimicrobial drugs.
Because awareness of Buruli ulcer disease is limited in 
regions where M. ulcerans is nonendemic, the potential for 
delayed diagnosis in such areas is increased. For persons 
with recent travel from M. ulcerans–endemic regions, Bu-
ruli ulcer disease should be considered in the differential 
diagnoses of unusual chronic cutaneous ulcers and skin ul-
cers nonresponsive to conventional therapy.
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*All patients were male. Except for negative smear results for patient 1, culture and smear results for all patients	were	positive.	QLD,	Queensland;	–, 
Information not available. 
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